title: Massive splenomegaly in myeloproliferative disorders treated by splenic artery infusion of cytarabine.
abstract: Ten patients with myeloproliferative disorders and massive splenomegaly were treated with splenic artery infusions of cytarabine. Nine patients demonstrated a response to treatment with reduction in spleen size. Three patients had the procedure repeated on subsequent occasions. Relief from pain was the most significant clinical benefit; lasting for up to 6 months regardless of the rate of splenic re-enlargement.
mesh_terms: D001772:Blood Cell Count / Q000187:drug effects; D003561:Cytarabine / Q000008:administration & dosage*; D006801:Humans; D007269:Injections, Intra-Arterial; D009196:Myeloproliferative Disorders / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000473:pathology; D013157:Splenic Artery; D013163:Splenomegaly / Q000000981:diagnostic imaging / Q000188:drug therapy*; D014057:Tomography, X-Ray Computed
chemical_list: D003561:Cytarabine